We earlier reported that exposure to arsenic at concentrations in ground water of India attenuated glial fibrillary acidic protein (GFAP) during brain development. Here, we validated the effects and explored mechanism in cultured astrocytes and developing rat brain. We hypothesized participation of epidermal growth factor receptor (EGFR), known to regulate GFAP. We found that arsenic inactivated EGFR, marked by reduced phospho-EGFR in astrocytes. Screening EGFR ligands revealed an arsenic-mediated attenuation in cellular and secreted-Heparin-binding EGF-like growth factor (HB-EGF). Furthermore, we observed that recombinant-HB-EGF cotreatment with arsenic blocked reduction in HB-EGF, secreted-HB-EGF and phospho-EGFR, which could be reversed by EGFR-inhibitor, gefitinib, suggesting that arsenic attenuated an HB-EGF/EGFR loop in astrocytes. This reduced HB-EGF/EGFR was essentially responsible for arsenic-induced astrocyte damage, obvious from a recombinant-HB-EGF-mediated recovery in GFAP levels and astrocyte morphology and reduction in astrocyte apoptosis, and the reverse by gefitinib. We found that arsenic also suppressed neuronal HB-EGF levels, which additionally contributed towards astrocyte damage. Exploring the pathways downstream of reduced HB-EGFR/EGFR revealed that an upregulated matrix metalloproteinase 9 (MMP9) within the astrocytes ultimately led to apoptosis and GFAP loss. Astrocytes and MMPs are known to regulate the blood-brain barrier (BBB) integrity, and hence we examined the effects of arsenic on BBB. We detected an arsenic-mediated increased BBB permeability, which could be blocked by recombinant-HB-EGF and MMP9 inhibitor, SB-3CT. Thus, our study indicates that via reduced astrocyte and neuronal HB-EGF signaling, arsenic may induce MMP9 levels and GFAP loss in astrocytes, which might adversely affect BBB integrity of the developing rat brain.
understanding the mechanism of arsenic-induced neurodevelopmental toxicity appears important.
Astrocytes participate in diverse aspects of brain development, and blood-brain barrier (BBB) formation is a major one (Joo, 1987) . Glial fibrillary acidic protein (GFAP) is an important cytoskeletal protein of astrocytes, and GFAP and astrocyte loss cause adverse effects on BBB permeability, resulting in compromised CNS functioning (Middeldorp and Hol, 2011; Sofroniew and Vinters, 2010) . We earlier reported that exposure to a heavy metal mixture that included arsenic, at concentrations prevalent in the ground water in India, suppressed GFAP levels and triggered behavioral anomalies in the 2-4 week-old rats (Rai et al., 2010) . Nonetheless, whether arsenic alone could have any impact on astrocyte integrity and functions remained less-known. In this study, we assessed the effect of arsenic on astrocytes, GFAP levels, BBB permeability, and the associated mechanism during brain development.
Epidermal growth factor receptor (EGFR), a member of the transmembrane receptor family with intrinsic intracellular tyrosine kinase activity, plays a critical role in astrocyte proliferation and viability (Yang et al., 2011) . EGFR undergoes prominent activation during astrogliosis, and an inhibited EGFR activity reduced GFAP levels and astrocyte hypertrophy (Yang et al., 2011) . Neuron-glia interaction involving EGFR signaling also regulated the signal transduction pathways in astrocytes (Gomes et al., 1999; Planas et al., 1998) . The key ligands that activate EGFR include EGF, transforming growth factor-alpha (TGFa), amphiregulin, betacellulin, epiregulin, and heparinbinding EGF-like growth factor (HB-EGF) (Schneider and Wolf, 2009) . EGF promotes astrocyte proliferation (Sartorius et al., 2016) and TGFa, amphiregulin, and betacellulin participate in region-specific functions within the astrocytes (Eib and Martens, 2002; Ma et al., 1994; Takenouchi et al., 1999) . HB-EGF expression has a distinct link with GFAP levels (Lebkuechner et al., 2015) , and an HB-EGF/EGFR signaling regulates proliferation, differentiation, and trophic actions of astrocytes during brain development (Puschmann et al., 2014) . The HB-EGF/EGFR signaling pathway is regulated by matrix metalloproteinase (MMP) group of zinc-endopeptidases, viz. MMP2 and MMP9, that trigger HB-EGF shedding and modulate glial functions (Ashok et al., 2016; Kim et al., 2017) . Additionally, EGFR also undergoes cross-talk with MMPs (Vouri et al., 2016) , and an inhibited EGFR signaling has been known to block MMP9 activation in glial cells (Wang et al., 2014) . A key pathological process enhancing BBB permeability included MMP-mediated damage to tight junctions in the developing brain (Chen et al., 2009) , associated with an altered EGFR activation (Yang et al., 2017) . However, the impact of arsenic exposure on the astrocytic EGFR signaling and MMP levels and whether they had any links with BBB formation is unknown.
In this study, we hypothesized that arsenic may have a toxic effect on astrocytes, GFAP, and BBB via participation of EGFR and MMP signaling in the developing brain. We investigated whether arsenic affected EGFR activation and expression levels of EGFR ligands. We examined the effect on MMPs and probed any link between EGFR and MMP in the arsenic-treated astrocytes. An intricate cross-talk control functions of brain cells (Gomes et al., 2001) , and we searched whether a glianeuron interaction could affect the EGFR and MMP signaling of astrocytes. We eventually explored the link between EGFR, MMP, GFAP, astrocyte integrity, and BBB within the developing brain of arsenic-treated rats.
MATERIALS AND METHODS

Reagents and Kits
Sodium arsenite solution (in vitro purpose), Evans Blue (EB) dye, poly-L-lysine, sodium chloride, sodium bicarbonate, 3-aminopropyltriethoxysilane, methanol, tris-HCl, tween 20, protease inhibitor cocktail (PIC), dithiothreitol (DTT), paraformaldehyde (PFA), Hoechst-33258 stain, bovine serum albumin (BSA), acrylamide, bis-acrylamide, SDS, sucrose, MTT [3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide], SB-3CT, CellLytic MT mammalian tissue and cell lysis buffer, triton-X-100, dimethyl sulfoxide (DMSO), gelatin, and calcium chloride were procured from Sigma Chemical Co. (St. Louis, MO). Sodium arsenite (in vivo purpose, 98.5% purity) and sodium borohydride were purchased from SD Fine Chemicals (Mumbai, India). Ponceau S stain, Coomassie brilliant blue R-250, sodium citrate, and sodium fluoride were purchased from Texas Biogene Inc. (Woodland, TX). Trypsin-EDTA, G5 supplement, Dulbecco's modified eagle medium: F12 (DMEM/F12), neurobasal medium, B27 supplement, N2 supplement, trypsin inhibitor, Hank's balanced salt solution (HBSS), PBS, antibiotic-antimycotic, fetal bovine serum (FBS), HB-EGF-siRNA, nontargeting (NT)-siRNA, and lipofectamine transfection reagent were purchased from Invitrogen (Carlsbad, CA). Recombinant HB-EGF was purchased from R&D systems (Minneapolis, MN). Prestained protein ladder was procured from Genetix Biotech Asia Pvt Ltd. (New Delhi, India). VECTASHIELD mounting medium was purchased from Vector Laboratories (Burlingame, CA) and tissue-freezing medium was purchased from Leica Microsystems (Heidelberger Strasse, Germany). Supersignal west femto maximum sensitivity substrate and ultrapure Hydrochloric acid were purchased from Thermo Scientific (Rockford, IL). In Situ Cell Death Detection Kit, Fluorescein for terminal deoxynucleotidyltransferase UTP nick end labeling (TUNEL) assay was purchased from Roche (Mannheim, Germany). Gefitinib (Iressa) was procured from Tocris biosciences (Bristol, United Kingdom). ApopNexin FITC Apoptosis detection kit, bicinchoninic acid (BCA) protein assay kit, propidium iodide, and polyvinylidene fluoride (PVDF) membrane were procured from Millipore (Temecula, CA). SYBR Green and qPCR kit were procured from Qiagen (Valencia, CA). ELISA kit for phospho-EGFR (p-EGFR, Tyr1068) was purchased from Ray Biotech Inc. (Norcross, GA). Ascorbic acid, potassium iodide, and arsenic solution (NIST traceable standard) were obtained from Merck (Darmstadt, Germany).
Antibodies
Goat polyclonal antibody to HB-EGF (cat no.-sc-1414) was purchased from Santa Cruz Biotechnology (Dallas, TX). Rabbit polyclonal to p-EGFR (cat no. 3777), EGFR (cat no. 2232), MAP2 (cat no.-4542), cleaved caspase-3 (cat no. 9661), and cleaved caspase-9 (cat no. 9507) antibodies were purchased from Cell Signalling Technology (Danvers, MA). Rabbit polyclonal MMP9 (cat no. ab 38898) and Iba1 (cat no. ab5076) antibodies were purchased from Abcam (Cambridge, MA). Rabbit polyclonal antibody to GFAP (cat no. G9269), CNPase (cat no. c 9743), mouse monoclonal antibody to b-actin (cat no. A5441), horseradish peroxidase (HRP)-conjugated secondary anti-rabbit IgG (cat no. A0545), and anti-mouse IgG (cat no. A9044) were from Sigma Chemical Co. (St Louis, MO) . Mouse monoclonal to GFAP (cat no. MAB360) antibody was purchased from Millipore (Temecula, CA). Alexa Fluor 488 goat anti-rabbit IgG, Alexa Fluor 546 goat anti-rabbit IgG, Alexa Fluor 488 goat anti-mouse IgG, and Alexa Fluor 594 chicken anti-goat IgG were from Invitrogen (Carlsbad, CA).
In Vivo Methods
Animals and Treatments Animal housing. All animal handling and surgical procedures were carried out in accordance with the current regulations of the Institutional Animal Ethics Committee (CSIR-IITR), and with its prior approval for using the animals. Timed pregnant Wistar rats were housed in a 12-h day and light cycle environment with the ad libitum availability of diet (Altromin 1324; Altromin Spezialfutter GmbH & Co, Germany) and reverse osmosis (RO) water. (Rai et al., 2010) by oral gavage (2-3 ml/kg body weight) from gestational day 5 to postnatal day (PND) 16 or PND23. Arsenic levels in RO water, detected through Atomic Fluorescence Spectrometry (AFS), were found to be below the limit of detection (LOD). Sodium arsenite solution was prepared by dissolving its accurately weighed amount in the RO water. Culling of animals was done at PND3 to a litter size of 6-10 comprising 3-5 males and 3-5 females. Each experiment contained an equal number of male and female pups randomly selected from individual litters. To identify the participation of HB-EGF and MMP9, respectively, in arsenic-treated rats, recombinant HB-EGF (100 ng) (Maurya et al., 2016) or the pharmacological inhibitor of MMP9, SB-3CT (15 mg/kg) (Ashok et al., 2016) were injected through intracerebroventricular (icv) route once in PND16 rat pups as described before (Cetin et al., 2007) . Briefly, the pups were anesthetized by intraperitoneal (ip) injection of ketamine and xylazine (60 and 20 mg/kg body weight, respectively) and positioned in stereotaxic frames (Stoelting Co., Wood Dale, IL). Recombinant HB-EGF or SB-3CT, 2 ll each, were inserted through bilateral injections in the cortex (stereotaxic coordinates: anteroposterior À1.2 mm, lateral 63.0 mm, and ventral À1.0 mm from the bregma; Khazipov et al., 2015) using a 10-ll Hamilton syringe fixed on the stereotaxic apparatus at a preset inject volume rate of 1 ll/min that autoregulated injection rate. The control rats were treated through icv injection with the vehicle (sterile PBS for recombinant HB-EGF and DMSO for SB-3CT). The cortex from the rat brain was isolated seventh day (PND23) after stereotaxic insertion. To identify the effects of EGFR inhibition, gefitinib (pharmacological inhibitor of EGFR, 5 mg/kg, obtained through standardization Supplementary Figure 1 ) and its vehicle (DMSO) were injected through ip route every third day in the rat pups from PND03 until PND21 (Jo et al., 2014; Wu et al., 2016) . Rat pups were sacrificed at PND16 and PND23 and the brain was dissected out. Cortical tissues were isolated, snap frozen in liquid nitrogen, and stored at À80 C until further analysis for atomic absorption, Western blotting, and immunohistochemistry.
Evaluation of arsenic. Arsenic levels in the PND16 rat brain cortex were measured following a previously described protocol with slight modification (Rai et al., 2010) . A standard solution (1 mg/ml) of arsenic was prepared by adding 10% ascorbic acid, potassium iodide, and HCl to the 1 mg/ml solution, and then standard curve plotted in the range of 0.2-5 ng/ml by serial dilution. For sample preparation, cortical tissues were digested in concentrated HNO 3 , overnight at 60 C, and treated with 10% ascorbic acid, potassium iodide and ultrapure HCl, followed by centrifugation at 9167 g for 10 min. Arsenic analysis in the supernatant was conducted by AFS (PG Instruments AF-420, Leicestershire, UK), equipped with an auto sampler, hydride generator and high intensity hollow cathode lamps. Manufacturer brand PF Win software was used for data integration and processing. The instrument was set at 50 mA and 200 C of lamp main current and Atomizer temperature, respectively, with scanning time of 15 s. For AFS analysis, standard solutions (1 ml) and sample solution (0.1 ml) were aspirated with reducer (10% sodium borohydride solution) and carrier liquid of 1.5 and 1 ml, respectively. LOD and limit of quantification (LOQ) of arsenic were calculated from the equation of standard deviation of the response and the slope as mentioned in ICH guideline; LOD ¼3Âr/s and LOQ ¼ 10Âr/s, where r and s are the standard deviation of the response and slope of the calibration curve, respectively.
Protein extraction and Western blotting (in vivo)
. Cortical tissues of 6 pups from 3 different litters per treatment groups were dissected out and homogenized in lysis buffer containing PIC and 1 mM DTT, and kept on ice for 20 min. The homogenates were then centrifuged for 30 min at 20 627 g and 4 C. The supernatant was collected and protein concentration determined by BCA assay, as per manufacturer's protocol. SDS-PAGE and Western blotting was then performed. Equal amount of protein samples (60 mg) and the prestained protein ladder were loaded onto 8%-12% tris-glycine polyacrylamide gel and immunoblotting was performed as previously described . PVDF membranes were probed overnight at 4 C with GFAP (1:2000), p-EGFR (1:1000), EGFR (1:1000), and MMP9 (1:1000) antibodies and then incubated with HRP-conjugated secondary antibody. Protein was visualized and images were captured through Amersham Imager 600 (GE Healthcare Life Sciences, Pittsburgh, PA) using Supersignal West Femto Maximum Sensitivity Substrate. The blots were then stripped and immunoblotted with b-actin (1:10 000) as a loading control. Protein expression relative to b-actin was quantified using Bio-Rad Quantity One image analysis software (Bio-Rad, Hercules, CA).
Fluorescence immunohistochemistry. Fluorescence immunohistochemistry of cerebral cortex in PND16 and PND23 rat pups was performed. Briefly, rats were anesthetized and perfused with 4% PFA and 0.2% picric acid in PBS. The whole brain was dissected out, postfixed in PFA overnight, and cryoprotected in 10%, 20%, and 30% sucrose sequentially. Five-micron coronal sections of the cerebral cortex were prepared using cryomicrotome (Microm HM 520; Labcon, Munich, Germany), in which same plane and position of cortical sections among different brain samples were maintained by referring to the Rat Atlas (Khazipov et al., 2015) . The sections were mounted on 3-aminopropyl-triethoxy-silane-coated slides, antigen retrieved with citrate buffer in water-bath at 65 C for 30 min, and blocked with 3% BSA in PBS. The sections were then probed with GFAP (Agarwal et al., 2015) .
TUNEL assay. TUNEL assay was carried out for in situ detection of apoptosis in astrocytes within the cerebral cortex of PND23 rat pups as described before (Rai et al., 2010) . Per treatment, 2-3 sections from each of 6 rat pups of 3 different litters were used. Briefly, 5-mm-thick coronal sections from PND23 rat pups were mounted on 3-aminopropyl-triethoxy-silane-coated slides and labeled with fluorescein-labeled dUTP in the presence of TdT at 37 C overnight. The sections were immunostained with anti-GFAP mouse antibody (1:400 dilution in PBS), incubated with Alexa Fluor goat anti-mouse (546) secondary antibody (1:800 dilution in PBS), and counterstained with Hoechst 33258 (0.2 mM). The slides were mounted in VECTASHIELD media and visualized under a fluorescence microscope (Nikon Instech Co. Ltd.). Apoptotic index was expressed as the number of TUNELpositive cells per 100 nuclei (Hoechst stained) in GFAPexpressing astrocytes from 5 randomly selected fields. ImagePro plus 5.1 software (Media Cybernetics Inc.) was used for cell counting.
EB extravasation. EB was used to assess the BBB permeability in rat brain as described earlier (Lin et al., 2010) . Briefly, PND23 rat pups (6 pups from 3 litters per treatment) were anesthetized and 3% EB in normal saline was injected slowly through the femoral vein (4 ml/kg), followed by transcardial perfusion with saline. The rat brain cortex was isolated, incubated overnight in formamide, homogenized, centrifuged at 13 201 g for 30 min and optical density of the supernatant samples measured at 620 nm using a microplate reader. For fluorescence assessment, EBinjected rats were transcardially perfused and 20-mm-thick coronal cryosections visualized under fluorescence microscope. Per treatment, 2 sections from each of 6 rat pups of 3 different litters were used for EB fluorescence.
In Vitro Methods
Primary Astrocyte Culture Astrocytes from the rat brain were isolated and cultured as described previously (McCarthy and de Vellis, 1980) . Briefly, cortices from PND1 old control rat pups were dissected out and rinsed in serum-free DMEM/F12 culture medium. After removal of meninges, which helped avoiding fibroblast contamination (Yang et al., 2006) , the cortices were dissociated into a cell suspension and digested with 0.05% trypsin/EDTA at 37 C for 15 min in the incubator. Cells were resuspended in DMEM/F12 with 10% heat-inactivated FBS (endotoxin levels 5 EU/ml), 100 U/ml penicillin and 100 mg/ml streptomycin, followed by centrifugation at 129 g for 10 min, and the pellet obtained was suspended in complete (DMEM)/F12 media. The cells were seeded onto poly-L-lysine-coated culture flasks (25 cm 2 ) at a plating density of 7Â10 5 cells per flask. After third day of culture, cells were supplemented with G5 (composed of biotin (1 mg/ml), basic FGF (5 mg/ml), EGF (10 mg/ml), human transferrin (50 mg/ml), insulin (5 mg/ml), hydrocortisone (3.6 mg/ml), and selenite (5.2 mg/ml)) for growth and expression of glial cells of astrocytic phenotype. The confluent astrocyte cells were subcultured in complete (DMEM)/F12 media without G5 supplement. Purity of the astrocyte cell culture was confirmed by coimmunostaining GFAP with neuron, oligodendrocyte and microglial markers (MAP2, CNPase and Iba1 respectively), and qPCR with fibroblast primers (Supplementary Figure 2) .
Primary Neuronal Culture
Embryonic (E16) cortical brain tissues were dissected out in HBSS, and neurons isolated as described previously (Ray et al., 1993) . Briefly, following trituration in neurobasal medium, the cell suspension was digested using 0.05% trypsin with EDTA, incubated for 10 min at 37 C, noncellular debris removed by gentle shaking and the remaining suspension centrifuged at 289 g for 10 min. The pellets were resuspended in neurobasal medium containing B-27 and N2 supplements, L-glutamine (0.5 mM), penicillin (100 units/ml) and streptomycin (100 mg/ml). 
Treatments in Astrocytes and Neurons
Astrocytes and neurons were separately plated in culture flasks (25 cm 2 ) at a plating density of 7Â10 5 cells per flask in respective complete culture media. After reaching 70%-80% confluence, the astrocytes and neurons were preincubated for 2 h in reduced serum medium (0.5% FBS in DMEM/F12 and without G5 supplement) and neurobasal medium respectively, and then treated with arsenic at concentrations closely matching that reaching the brain following in vivo treatments (Table 1) . For examining the effect of arsenic on astrocyte and neuronal viability, cells from 5 independent primary culture preparations were treated with 0-40 lM of arsenic for 0-24 h. For assessing dose-dependent effects of arsenic on morphology and GFAP, MAP2, HB-EGF, and MMP9 levels, cells from 3-4 independent culture preparations for each were treated with 0-15 lM of arsenic for 18 h. To determine EGFR activation, astrocytes were treated with 0.1 and 2.5 lM of arsenic for 0-18 h using cells from 4 independent culture preparations. To investigate the participation of p-EGFR, HB-EGF, and MMP9 through Western blotting or immunocytochemistry, astrocytes from 4-6 independent culture preparations were pretreated for 1 h with 10 mM gefitinib (Ciardiello, 2000) , 0.5 ng/ml recombinant HB-EGF or 10 mM SB-3CT (pharmacological inhibitor of MMP9) respectively (Gu et al., 2005) , and cotreated with arsenic (2.5 lM) for 18 h.
MTT Assay
The astrocytes and neurons were seeded onto 96-well culture plates (20 000 cells per well), allowed to grow until 70%-80% confluence, preincubated in reduced serum and neurobasal medium, respectively, for 2 h and then treated with arsenic. The arsenic-treated cells were incubated with MTT reagent (10.4 mg/ml) and absorbance determined at 595 nm, with a background subtraction at 655 nm using a Microplate reader (Tecan, infinite 200 PRO, Switzerland) . Independent experiments were performed from 5 different culture preparations and in triplicates per plate.
Protein Extraction and Western Blotting (In Vitro)
Independent experiments for western blotting were performed in T-25 culture flasks (cell density of 7Â10 5 ). After specific treatments, astrocyte and neuronal cells were lysed using lysis buffer and cooled on ice. Cells were scraped, centrifuged at 4 C and 20 627 g for 30 min and clear supernatant was collected. Western blotting of samples was performed following the basic method as done for in vivo experiments using GFAP (1:2000), HB-EGF (1:1000), MMP9 (1:1000), MAP2 (1:2000) and anti-b-actin (1:10 000) antibodies.
Immunocytochemistry
Immunocytochemistry of astrocyte and neuronal cells were carried out in five 4-well chamber slides from 5 different culture preparations. Briefly, the cells were subcultured and plated onto poly-L-lysine-coated chamber slides at a cell density of 3.5-5 Â 10 4 . Upon 80% confluence, astrocytes were preincubated for 2 h in reduced serum medium and then cotreated with arsenic, recombinant HB-EGF þ arsenic, gefitinib þ recombinant HB-EGF þ arsenic or SB-3CT þ arsenic for 18 h at 37 C in CO 2 incubator. The neurons were preincubated in neurobasal media and treated with arsenic for 18 h. The cells were fixed in 4% PFA (1 h) at room temperature, preincubated with PBS, permeabilized in methanol at À20 C for 30 min, washed in PBS and incubated with 3% blocking serum. The astrocytes and neurons were incubated overnight at 4 C with GFAP (1:400) and MAP2 (1:400) antibodies respectively and then with Alexa Fluor 488 goat antimouse or anti-rabbit IgG conjugate (1:800) for 2 h, followed by mounting and visualization with a fluorescence microscope at 60Â objective spanning the slide surface. To identify area, perimeter and projection number of astrocytes and the number and length of dendritic branches and area of dendritic tree in neurons (Ebrahimi et al., 2016) a consistent morphology for the majority of cells (as visualized under 60Â objective) was taken into consideration. Images of the astrocytes and neurons were captured under a 100Â objective using NIS-Elements microscope imaging software and analyzed with Image J 1.43q and NeuriteQuant plugin of Image J 1.43q softwares, respectively.
ELISA
The p-EGFR, EGFR and secreted HB-EGF (s-HB-EGF) levels were determined by ELISA. Briefly, 20, 000 astrocyte or neuronal cells/ well (100 ll/well) were seeded onto 96-well plates and incubated overnight at 37 C in a CO 2 incubator until cells were 70%-80%
confluent. The cells were treated with vehicle, arsenic, recombinant HB-EGF þ arsenic or gefitinib þ recombinant HB-EGF þ arsenic in reduced serum media. For p-EGFR and EGFR, the cells were washed in buffer, incubated with fixing solution for 20 min at room temperature, and then with blocking buffer for 1 h at 37 C in dry bath. Anti-p-EGFR (Tyr1068) and anti-EGFR primary antibodies were added to each well and incubated for 2 h at room temperature. For HB-EGF, the astrocyte and neuronal media were centrifuged separately at 1000 g for removal of particulates. The supernatant obtained was added to HB-EGF antibody-coated plates (manually coated at 1:300 dilution in coating buffer) and incubated overnight at 4 C. After washing, the plates were incubated with HRP conjugated secondary antibody for 2 h at room temperature, rewashed, and incubated with 3, 5, 5-tetramethyl benzidine for 30 min at room temperature in dark. Stop solution was added and absorbance measured at 450 nm immediately using a Micro-plate reader. The detection range of the ELISA kits for quantitative measurements of p-EGFR and anti-EGFR was 20-100 ng/ml. HB-EGF levels in the astrocyte and neuronal media were determined from the curve obtained using standards (0, 15.6, 31.2, 62.5, 125, 250 , 500, and 1000 pg/ml) run along with the samples. Six independent experiments in triplicates were carried out from 6 different culture preparations
Real-Time PCR Astrocyte and neuronal cells in 6-well culture plates (3.0Â10 5 cells) were preincubated in reduced serum or neurobasal medium respectively for 2 h, and then treated with arsenic. After 18 h, medium was aspirated, and RNA isolated through TRIzol method. The RNA obtained was then dissolved in RNase-, DNase-free water, quantified, and subjected to complementary DNA (cDNA) synthesis using Omniscript RT Kit. The cDNA was amplified with an ABI PRISM 7900 HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA) using SYBR Green dye over 40 cycles of sequential reactions of 95 C (10 min), 95 C (10 s), 60 C (30 s), and 72 C (30 s). Relative mRNA expression for the treatments was calculated using DDCt method. Optimum primer pairs (Table 2) for GFAP, MAP2, EGFR ligands (EGF, HB-EGF, TGFa, betacellulin, epiregulin and amphiregulin), MMP2, MMP7, MMP9, S100A4, ErbB1, ErbB4, Notch1, Notch2, Notch3, Notch4, and internal housekeeping control gene, glyceraldehydes 3-phosphate dehydrogenase (GAPDH), was designed using Primer Express version 2.0.0 (Applied Biosystems). Data were evaluated with QuantStudio Real-Time PCR Software v1.0. Five independent experiments in triplicates were carried out from 5 different culture preparations.
Flow Cytometry
To detect astrocyte cell death and apoptosis, propidium iodide uptake assay was performed. Briefly, astrocyte cells in 6-well plates (3.0 Â 10 5 cells/well) were trypsinized, centrifuged at 129 g for 5 min. Cell pellets were washed and resuspended in PBS and incubated with propidium iodide (1 mg/ml) for 30 min on ice in dark. Propidium iodide-positive cells were detected in BD FACScanto II flow cytometer (Becton-Dickinson), and a minimum 10 000 cells per sample were counted. Data were analyzed using BD FACS Diva software (Becton-Dickinson). Six independent experiments in triplicates were carried out from 6 different culture preparations.
Gelatin Zymography
Enzymatic activity of MMP9 was estimated by gelatin zymography as previously described (Toth et al., 2012) . Astrocytes were first plated in 6-well plates (9.6 cm 2 ) at a plating density of 3x10 5 cells per flask. The 70%-80% confluent cells were treated with arsenic, recombinant HB-EGF þ arsenic or gefitinib þ recombinant HB-EGF þ arsenic for 18 h. Equal amount of cell supernatant (100 ml) was mixed with nonreducing sample buffer (0.125 M Tris-HCl, 20% glycerol, 4% SDS, 0.01% bromophenol blue, pH-6.8) and then loaded on 8% SDS-PAGE gel copolymerized with 4 mg/ml gelatin. After electrophoresis, the gel was washed twice in 2.5% Triton X-100 and then with Milli Q water to remove SDS and incubated in activation buffer (50 mM Tris, 0.15 M NaCl, 10 mM CaCl 2 , 0.02% NaN 3 , pH-7.4) for 48 h at 37 C. The gel was stained for 1 h with 0.1% Coomassie Brilliant Blue R-250, followed by destaining. Imaging was done using gel documentation system (Bio-Rad), and data were analyzed through Quantity One software. Four independent experiments were carried out from 4 different culture preparations.
siRNA Transfection Primary neuronal cells were transfected using lipofectamine reagent as per manufacturer's instructions and following a previously described protocol . the nontargeting siRNA (NT-siRNA) (5 nM) or HB-EGF-siRNA (siRNA ID-197366, Gene ID: 25433) (5 nM), and lipofectamine reagent were suspended in serum free medium for 30 min at 37 C and allowed to form complex with each-other. The neurons were grown up to 70%-80% confluence, incubated in reduced serum medium for 2 h and then treated overnight with the siRNA and lipofectamine reagent complex. The media were replaced with complete media for another 24 h, and HB-EGF-siRNA-mediated HB-EGF suppression in neurons were verified (Supplementary Figure 3) . Independent experiments were performed in 5 T-25 culture flasks from 5 different culture preparations.
Treatment of Neuronal Conditioned Media on Astrocytes
Around 70%-80% confluent neurons were preincubated for 2 h in neurobasal medium and treated with arsenic (2.5 lM) for 18 h. To examine whether neuronal HB-EGF affected the astrocytes, arsenic and recombinant HB-EGF (0.5 ng/ml) were cotreated in neurons for 18 h. To verify the participation of neuronal HB-EGF, neurons were treated with HB-EGF-siRNA and then cotreated with recombinant HB-EGF and arsenic for 18 h. Fifty percent of the condition media from neurons of the above sets were mixed with equal volumes of reduced serum medium of astrocytes, and combined media were then transferred onto the primary astrocytes and incubated for 18 h. The astrocytes were assessed for HB-EGF, p-EGFR, MMP9, and GFAP levels, apoptosis and morphology.
Statistics
All statistical analyses were performed with GraphPad PRISM software (GraphPad software, Inc.). To ascertain the dose and time effects of arsenic (MTT assay and ELISA for p-EGFR), Twoway ANOVA followed by Bonferroni post hoc test was performed. Homogeneity of variance was tested using Levene's test (SPSS software). For other experiments, One-way ANOVA followed by Bonferroni post hoc tests were performed. Prior to running parametric tests, the homogeneity of variances was tested.
RESULTS
Arsenic Reduces GFAP Levels and Induces Morphological Alterations in Astrocytes
We treated developing rats with environmentally relevant doses of arsenic and detected increased arsenic levels in the developing brain (Table 1) . We then assessed the effect of arsenic on cultured primary astrocytes by treating the cells with arsenic at the range of 0.01-10 lM, which included the levels detected in developing rat brain (Table 1) . We detected an arsenic-mediated dose and time-dependent reduction in the viability of primary astrocytes ( Figure 1A ; Supplementary Figure 4) . We verified the effects of arsenic on GFAP mRNA and protein levels. We detected a dose and time-dependent reduction in GFAP mRNA (Figs. 1B and 1D ) and protein levels (Figs. 1C and 1E ). The effects were most significant for 2.5 lM and at 18 h time point of arsenic treatment. We assessed the effect of arsenic on astrocyte morphology. We detected a significant reduction in the area, perimeter and projection number of primary astrocytes ( Figure 1F ). We validated the arsenic-mediated altered astrocyte morphology, in vivo, in the developing rat brain ( Figure 1G ; Supplementary Figure 5 ).
Arsenic Suppresses HB-EGF/EGFR Signaling in Astrocytes
We examined the mechanism of GFAP reduction in arsenictreated primary astrocytes, and particularly assessed whether EGFR participated in the arsenic-mediated GFAP loss. Interestingly, we observed that arsenic triggered EGFR inactivation, marked by attenuated p-EGFR levels ( Figure 2A) . Screening for the participation of EGFR ligands revealed a reduced expression of HB-EGF mRNA. The mRNA levels of other EGFR ligands were relatively less affected ( Figure 2B ). We validated the dose and time-dependent HB-EGF reduction through Western blotting ( Figure 2C, Supplementary Figure 6 ) that demonstrated a strongly significant effect (p < .001) for 2.5 lM and at 18 h timepoint of arsenic treatment. HB-EGF shedding releases secreted-HB-EGF (s-HB-EGF) that activates EGFR (Peng et al., 2003) , and hence, we examined the effect of arsenic on s-HB-EGF. We detected an arsenic-mediated dose and time-dependent reduction in s-HB-EGF ( Figure 2D, Supplementary Figure 6 ) of astrocytes. To verify whether the attenuated HB-EGF and p-EGFR could be truly linked, we cotreated astrocytes with recombinant Figure 2 . Arsenic attenuates p-EGFR and HB-EGF, which is inhibited by HB-EGF and retained by HB-EGF þ gefitinib treatments in rat primary astrocytes. A, Arsenicmediated reduction in p-EGFR (detected through ELISA) relative to 0 min in rat primary astrocytes. Data represent means 6 SE of 4 independent experiments. Two-way ANOVA analysis of interaction between dose and time (F¼235.30, df¼8, p<.0001), main effects of dose (F¼3013.05, df ¼1, p<.0001), and main effects of time (F¼4358.01, df ¼ 8, p< .0001) indicated significant effects. B, Different EGFR ligands/GAPDH mRNA levels relative to 0 lM in arsenic-treated (18 h) rat primary astrocytes. Data represent means 6 SE of 3 independent experiments in triplicates. C, Representative Western blot showing dose-dependent reduction in HB-EGF/b-actin protein levels relative to 0 lM of arsenic treatment in rat primary astrocytes. D, ELISA data showing dose-dependent reduction in secreted HB-EGF levels in arsenic-treated rat primary astrocytes. Data represent means 6 SE of 3 independent experiments. Rat primary astrocytes were treated with V, arsenic (2.5mM), recombinant-HB-EGFþarsenic or gefitinibþrecombinant-HB-EGFþarsenic for 18 h. E and F, p-EGFR (ELISA) (E) and representative Western blot and densitometry of HB-EGF/b-actin protein levels (F) compared with V. G. Secreted HB-EGF levels (ELISA) following indicated treatments (18 h) in rat primary astrocytes. Data represent means 6 SE of 3 independent experiments. ***p<.001, **p<.01, and *p<.05 compared with 0 lM (B, C and D), V (E, F, and G) or as indicated. Abbreviations: HB-EGF, Heparin-binding EGF-like growth factor; EFGR, epidermal growth factor receptor; GAPDH, glyceraldehydes 3-phosphate dehydrogenase.
HB-EGF þ arsenic for 18 h. We found that the recombinant HB-EGF blocked arsenic-mediated changes in p-EGFR ( Figure 2E ), and also cellular HB-EGF ( Figure 2F ) and s-HB-EGF ( Figure 2G ) levels, indicating that arsenic reduces an HB-EGF-dependent EGFR activation and HB-EGF induction in the astrocytes. Alternatively, to examine whether EGFR could regulate HB-EGF expression levels, we cotreated the astrocytes with recombinant HB-EGF þ arsenic and an EGFR inhibitor, gefitinib. We detected that gefitinib cotreatment inhibited the effects of recombinant HB-EGF on p-EGFR ( Figure 2E ) and cellular ( Figure 2F ) and secreted HB-EGF ( Figure 2G ) in arsenic-treated astrocytes, indicating that arsenic suppresses an HB-EGF/EGFR signaling in the astrocytes. To understand the effects in the developing rat brain, in vivo, we first examined the expression levels of HB-EGF and p-EGFR in the astrocytes of arsenic-treated rats. We detected that arsenic reduced HB-EGF ( Figure 3A , Supplementary Figure 7 ) and p-EGFR ( Figure 3B , Supplementary  Figure 7 ) expression levels in the astrocytes of the developing rat brain. To verify the participation of HB-EGF, we inserted recombinant HB-EGF into the brain of arsenic treated rats. We found that recombinant HB-EGF could enhance the HB-EGF ( Figure 3A ) and p-EGFR ( Figure 3B ) expression levels, suggesting arsenic-mediated attenuation of HB-EGF/EGFR signaling within the astrocytes of developing rat brain.
Attenuated HB-EGF/EGFR Signaling Suppresses GFAP, Alters Astrocyte Morphology, and Promotes Astrocyte Apoptosis Following Arsenic Treatment
We examined whether the attenuated HB-EGF/EGFR signaling could have any link with reduced GFAP. We observed that treating primary astrocytes with recombinant HB-EGF þ arsenic enhanced the GFAP levels and restored astrocyte morphology, and a gefitinib cotreatment failed to do so (Figs. 4A and 4B) . Thus, our data suggest that the arsenic-mediated decrease in HB-EGF/ EGFR signaling causes GFAP reduction in primary astrocytes. We earlier observed that arsenic could induce apoptosis in astrocytes , and here we examined if reduced HB-EGF/EGFR signaling could be responsible for the apoptosis. We detected that recombinant HB-EGF cotreatment reduced arsenic-induced apoptosis in primary astrocytes, and gefitinib blocked the HB-EGF-mediated changes ( Figure 4C) .
We examined the participation of HB-EGF, in vivo, and found that recombinant HB-EGF treatment reinstated the GFAP levels ( Figure 5A ) and astrocyte morphology ( Figure 5B ) in the arsenictreated developing rats, whereas gefitinib abolished the effects of HB-EGF. (The vehicles for arsenic, recombinant HB-EGF, SB-3CT, and gefitinib had no effect on GFAP levels; Supplementary  Figure 8 ). We additionally detected that HB-EGF decreased arsenic-induced apoptosis in astrocytes of the developing rat brain, which was inhibited by gefitinib ( Figure 5C ). Thus, results from this figure identify a decreased HB-EGF/EGFR signaling as responsible for reduced GFAP, altered astrocyte morphology and enhanced astrocyte apoptosis in the developing rat brain.
Arsenic Triggers a Reduced HB-EGF-Dependent MMP9 Induction in Astrocytes
It is generally known that increased active form of MMPs enhances HB-EGF cleavage and the generation of s-HB-EGF (Ashok et al., 2016) . Alternatively, it has been reported that increased EGFR signaling modulates MMP expression (Wang et al., 2014; Yue et al., 2010) . Because we found an arsenic-mediated altered s-HB-EGF and EGFR, we probed whether arsenic had any effects on the MMPs. We first examined the effect in primary astrocytes and detected an enhanced MMP9 expression following arsenic treatment. The other MMPs were relatively less affected ( Figure 6A ). Western blotting validated the arsenicmediated increased MMP9 ( Figure 6B ). We measured MMP9 activity in culture supernatant by gelatin zymography and detected an arsenic-mediated dose-dependent increase in MMP9 activity ( Figure 6C ). To understand if the altered HB-EGF signaling had any links with MMP9, we cotreated the arsenictreated astrocytes with recombinant HB-EGF and assessed the MMP9 levels. Conversely, we treated the astrocytes with the MMP9 inhibitor, SB-3CT, and measured the HB-EGF levels. We found that recombinant HB-EGF suppressed MMP9 levels ( Figure 6D ) and activity ( Figure 6E ), whereas SB-3CT failed to affect the cellular HB-EGF and s-HB-EGF levels ( Figure 6F ). We further observed that gefitinib cotreatment inhibited the effects of recombinant HB-EGF on MMP9 level ( Figure 6D ) and activity ( Figure 6E ) in arsenic-treated astrocytes. Thus, our data indicate that the attenuated HB-EGF stimulates active-MMP9 levels in the arsenic-treated astrocytes. Corroborating the in vitro observation, we detected an increased MMP9 expression in the arsenic-treated developing rat brain astrocytes, in vivo, and a reduction in MMP9 through recombinant HB-EGF þ arsenic cotreatment ( Figure 6G, Supplementary Figure 9 ).
Arsenic-Mediated Changes in Astrocytes Are MMP9-Dependent
We then verified whether the increased MMP9 affected the astrocytes. We cotreated arsenic-treated astrocytes with SB-3CT, and examined the GFAP levels, astrocyte morphology, and astrocyte apoptosis. We found that SB-3CT could reinstate GFAP levels ( Figure 7A ) and astrocyte morphology ( Figure 7B ), and reduce apoptosis ( Figure 7C ) in the arsenic-treated primary astrocytes.
For in vivo verification, we inhibited MMP9 levels using SB-3CT (Supplementary Figure 10) and examined the effects on the astrocytes. We detected an SB-3CT-mediated recovery in GFAP levels ( Figure 8A ), astrocyte morphology ( Figure 8B ), and apoptosis ( Figure 8C ) in the brain of arsenic-treated developing rats.
Arsenic Reduces HB-EGF and s-HB-EGF Levels of Neurons
We then examined whether arsenic had any effects on the neuronal HB-EGF levels in the developing rat brain. Through coimmunolabeling of HB-EGF with the neuronal marker, MAP2, we detected an arsenic-mediated attenuation in the HB-EGF levels of neurons in the developing rat brain ( Figure 9A,  Supplementary Figure 11) .
We examined the effects of arsenic on cultured primary neurons, and detected an arsenic-mediated dose-dependent decrease in neuronal cell viability ( Figure 9B ). We also observed an alteration in neuronal morphology, marked by reduction in dendritic branch number, dendritic length and dendritic tree area ( Figure 9C ). Additionally, we detected an arsenic-mediated dose-dependent reduction in MAP2 levels of primary neurons ( Figure 9D; Supplementary Figure 12) . Examining the effect of arsenic on neuronal HB-EGF showed a dose-dependent decrease in cellular HB-EGF ( Figure 9E; Supplementary Figure 12 ) and s-HB-EGF ( Figure 9F ) levels. We examined the effect of arsenic on the neuronal MMP9 levels, and detected no change ( Figure 9G ).
Reduced Neuronal HB-EGF Affects the HB-EGF/EGFR Signaling of Astrocytes, Inhibiting GFAP and Astrocyte Integrity Following Arsenic Treatment
We hypothesized that the attenuated s-HB-EGF from neurons may contribute towards the altered EGFR activation and hence HB-EGF/EGFR signaling of astrocytes. To assess this, we measured the HB-EGF, s-HB-EGF and p-EGFR levels of primary astrocytes following treatments with neuronal conditioned medium. We detected that conditioned medium from arsenictreated neurons attenuated HB-EGF ( Figure 10A ), s-HB-EGF ( Figure 10B ), and p-EGFR ( Figure 10C ) levels of astrocytes. We further observed that the conditioned medium from recombinant HB-EGF þ arsenic-treated neurons inhibited the changes in astrocytes. To recognize that the attenuated s-HB-EGF of neurons was truly responsible for the changes in HB-EGF and p-EGFR levels of astrocytes, we treated neurons with HB-EGFsiRNA and cotreated with recombinant HB-EGF þ arsenic. We found that neuronal conditioned medium from this set reduced the HB-EGF, s-HB-EGF and p-EGFR levels of the astrocytes compared with that from recombinant HB-EGF þ arsenic-treated neurons (Figs. 10A-C) . (To be noted recombinant HB-EGF could induce neuronal HB-EGF and s-HB-EGF and HB-EGF-siRNA suppressed s-HB-EGF levels; Supplementary Figure 13) . We examined whether the attenuated neuronal HB-EGF contributed towards increased MMP9 in astrocytes, and detected that conditioned medium from arsenic-treated neurons enhanced the MMP9 levels of astrocytes, and treatment with recombinant HB-EGF blocked the change ( Figure 10D ). Additionally, conditioned medium from HB-EGF-siRNA þ recombinant-HB-EGF þ arsenic-treated neurons reinstated the arsenic-induced MMP9 levels of astrocytes ( Figure 10D ). sentative gel zymogram and densitometry of MMP9 activity (E) relative to V in rat primary astrocytes following indicated treatments. Data represent means 6 SE. Rat primary astrocytes were treated with V, arsenic or SB-3CTþarsenic for 18 h. F, Representative western blot and densitometry of HB-EGF/b-actin protein levels relative to V (LHS) and ELISA data for secreted HB-EGF levels (RHS). Data represent means 6 SE of 4 experiments. ***p<.001, **p<.01, and *p<.05 compared with 0 lM (A, B, and C), V (D, E, and F) or as indicated. Rat dams were treated with arsenic, and their PND16 pups were treated with recombinant HB-EGF and examined at PND23. G, Fluorescent photomicrographs (60Â) and quantification relative to V of MMP9 and GFAP fluorescence co-immunostaining, counterstained with nuclear Hoechst, in cerebral cortical sections.
"Enlarged" represents magnification of the inset within "merged" image. Quantitative data represent means 6 SE. ***p<.001 and **p<.01 compared with V or as indicated. Abbreviations: HB-EGF, Heparin-binding EGF-like growth factor; matrix metalloproteinase; GAPDH, glyceraldehydes 3-phosphate dehydrogenase.
To examine whether the attenuated neuronal HB-EGF contributed towards astrocyte damage, we treated the astrocytes with conditioned medium from arsenic or recombinant HB-EGF þ arsenic-treated neurons. We detected that the conditioned medium from arsenic-treated neurons attenuated GFAP ( Figure  10E ), altered the astrocyte morphology ( Figure 10F ) and enhanced astrocyte apoptosis ( Figure 10G ), whereas recombinant HB-EGF inhibited these changes (Figs. 10E-G) . To verify the contribution of neuronal HB-EGF, we treated astrocytes with neuronal conditioned medium from HB-EGF-siRNA þ recombinant HB-EGF þ arsenic-treated neurons. Upon administering this conditioned medium to the astrocytes, we detected a significantly attenuated GFAP (Figure 10E ), altered astrocyte morphology ( Figure 10F) , and enhanced astrocyte apoptosis ( Figure 10G ) compared with that from recombinant HB-EGF þ arsenic-treated neurons. Thus, our data indicate that the attenuated neuronal HB-EGF and s-HB-EGF participated in GFAP reduction, morphology changes and apoptosis enhancement in astrocytes.
Arsenic Promotes BBB Damage and HB-EGF Restores BBB Integrity
We examined the effect of arsenic on the BBB and verified an arsenic-mediated dose-dependent increase in BBB permeability, marked by enhanced EB absorbance ( Figure 11A ) and fluorescence ( Figure 11B ) within the developing rat brain. To identify if MMP9 was truly responsible for BBB damage, we cotreated arsenic with MMP9 inhibitor, SB-3CT, in the developing rats. We detected a SB-3CT-mediated restoration of EB absorbance ( Figure 11A ) and fluorescence ( Figure 11B ), which indicated that arsenic-induced MMP9 participates in BBB damage within the developing rat brain. To ultimately identify the link with HB-EGF, we examined the effect of arsenic þ recombinant HB-EGF on the BBB permeability. We observed that recombinant HB-EGF could block the arsenic-induced EB absorbance ( Figure 11A ) and fluorescence ( Figure 11B ). Thus, our results indicate that the attenuated HB-EGF-dependent active MMP9 was responsible for arsenic-mediated BBB damage in the developing rat brain. Thus, our results suggest an arsenic-mediated (1) inactivation of HB-EGF/s-HB-EGF/EGFR signaling, which enhanced a downstream MMP9 expression within the astrocytes and (2) decreased neuronal HB-EGF/s-HB-EGF that further inactivated the HB-EGF/s-HB-EGF/EGFR signaling of astrocytes. The altered HB-EGF and MMP9 signaling culminated into a reduced GFAP, changed astrocyte morphology and augmented astrocyte apoptosis within the developing rat brain. The effect could be 
DISCUSSION
Our study provides the first evidence that arsenic attenuates GFAP expression and impairs astrocyte and BBB integrity via an attenuated HB-EGF/EGFR-dependent increased MMP9, where both the astrocytes and neurons contribute.
Corroborating our earlier in vivo findings in the developing rat brain (Rai et al., 2010) , the current study revealed an arsenicmediated reduced GFAP in the primary astrocytes. GFAP cytoskeletal network plays an important role in preserving astrocyte shape (Middeldorp and Hol, 2011) , and similarly, here we observed that arsenic had a marked impact on the cell Figure 11 . Arsenic promotes dose-dependent EB extravasation, and HB-EGF and SB-3CT treatments inhibit the arsenic-induced changes in developing rat brain.
Cerebral cortex from V, arsenic, arsenicþHB-EGF and arsenicþSB-3CT-treated rats were examined for BBB permeability following EB injection. A, Absorbance relative to V measuring EB extravasation in the rat brain. ***p<.001, **p<.01, and *p<.05 compared with V or as indicated. B, Representative photomicrograph (20Â) shows EB fluorescence co-stained with nuclear Hoechst in rat brain. Abbreviations: HB-EGF, Heparin-binding EGF-like growth factor; BBB, blood-brain barrier; EB, Evans Blue. morphology. Astrocyte structure, particularly the filamentous processes contribute towards glia-neuronal interactions and several physiological functions of the brain (Middeldorp and Hol, 2011) . Hence, our results indicate that damaged astrocytes could be a major reason behind reported neurotoxic effects of arsenic, viz., an altered neurite growth, synaptic potential, neurobehavior, etc. (Krü ger et al., 2007; Tolins et al., 2014) .
We reveal that arsenic attenuated the astrocyte viability via enhanced apoptosis, where we found that the FBS content in the medium had a very little impact (Supplementary Figure 14) . Supportively, the participating molecules, viz. p-EGFR, GFAP, HB-EGF, and MMP9 (Supplementary Figure 14) had also been hardly affected by the serum levels, offering a strong support for exclusive participation of arsenic in astrocyte damage, where serum proteins probably played insignificant role.
A key aim of the present study was to identify the mechanism triggering astrocyte damage within the developing brain. We revealed an arsenic-mediated EGFR inactivation and also demonstrated a restored EGFR activation to be protecting against astrocyte and GFAP damage. Studies portray an activated EGFR to stimulate the conversion of quiescent and activated astrocytes to a greater astrogliosis-like situation, thereby triggering cerebral injury (Planas et al., 1998; Yang et al., 2011) . Our findings, on the other hand, enlighten the necessity of a normally activated EGFR in restoring normal astrocyte integrity. Thus, the current study provides quite breakthrough on the role of EGFR in normal astrocytes and during GFAP downregulation, opposed to that in astrogliosis. We screened and spotted HB-EGF ligand as the pivotal regulator of EGFR signaling, and essentially identified an attenuated HB-EGF/EGFR signaling to be accentuating the arsenic-induced astrocyte damage. Our findings relate to an earlier observation that suggested the participation of normal HB-EGF/EGFR signaling in astrocyte survival (Maurya et al., 2012) . Sustaining this concept, we found that HB-EGF alone was capable of enhancing HB-EGF and p-EGFR levels in astrocytes of the developing brain, with a moderate impact on GFAP. Supportively, we observed that EGFR inhibition using gefitinib not only blocked EGFR activation but also triggered a Figure 12 . Proposed schematic showing that arsenic attenuates astrocyte and neuronal HB-EGF signaling and promotes MMP9-dependent astrocyte loss that may lead to BBB damage. Arsenic inactivates EGFR (1) and attenuates HB-EGF synthesis (2) and secretion (3), resulting in a suppressed HB-EGF/EGFR-signaling loop (4) in the astrocytes. Reduced neuronal HB-EGF (5) and s-HB-EGF (6) contribute to this attenuated HB-EGF/EGFR-signaling loop of astrocytes. Downstream of the reduced HB-EGF/ EGFR signaling, increased active MMP9 (7) leads to GFAP reduction, morphology alteration and apoptosis enhancement in astrocytes (8). These effects culminate in increased BBB damage (9) in the arsenic-treated developing rat brain. Abbreviations: HB-EGF, Heparin-binding EGF-like growth factor; MMP, metalloproteinase; EGFR, epidermal growth factor receptor; BBB, blood-brain barrier; GFAP, glial fibrillary acidic protein.
modest reduction in GFAP within the developing brain (Supplementary Figure 15) . Thus, it may be presumed that arsenic-mediated loss in astrocyte integrity is partially due to the disruption of basal HB-EGF/EGFR autocrine/paracrine signaling, and that treatment with arsenic may influence the effects of HB-EGF and EGFR and vice versa within astrocytes of the developing brain. Using arsenic-treated cells, our results additionally link the significance of this signaling in preventing astrocyte apoptosis and restoring astrocyte morphology and BBB integrity, suggesting the importance of HB-EGF/EGFR signaling in astrocyte biology. An arsenic-mediated increase in cleaved caspase-3 and 9, and their reduction upon HB-EGF treatment (Supplementary Figure 16) support the protective role of this ligand against arsenic-induced apoptosis. In terms of EGF receptors, particularly ErbB1 and ErbB4 having known links with prosurvival effects of HB-EGF Oyagi and Hara, 2012), our preliminary observation indicated an arsenic-mediated attenuation in ErbB1 rather than ErbB4 (Supplementary Figure 17) . However, studies validating the specific participation of ErbB1 in preventing astrocyte apoptosis and BBB disintegration, particularly upon arsenic exposure, remain essential.
The present study establishes a preferential link between arsenic and HB-EGF compared with the other EGFR ligands, as evident from unaltered mRNA levels of the latter. HB-EGF acts as a key trophic factor during brain development and repair, and essentially maintains astrocyte viability, supporting metabolic functions of the cell (Kornblum et al., 1999) . However, it has been reported that HB-EGF failed to have any impact on the GFAP levels of normal astrocytes (Puschmann et al., 2014) . Strikingly, in our study, we observed that arsenic suppressed the normal cellular morphology and GFAP levels of astrocytes, and HB-EGF restores the same. Thus, our findings suggest that functioning of the ligand is situation-based, triggering disparate responses in injured (in ours) versus normal astrocytes reported earlier. Nonetheless, the current study supports the concept that HB-EGF generally plays a protective role (Kornblum et al., 1999) , shielding against damage to astrocytes and thereby the CNS.
Exploring downstream signaling pathways of HB-EGF revealed that the attenuated HB-EGF/EGFR pathway in astrocytes executed its effects via upregulated MMP9. Although there have been several correlative studies between MMP9 and EGFR, which demonstrated an augmented EGFR-dependent MMP9 induction in glial metastases (Zhao et al., 2010) , our data provide a rare insight into an inverse relation between activated EGFR and MMP9 in the primary astrocytes. Thus, supporting an earlier study showing gefitinib-mediated MMP9 upregulation (Umbreit et al., 2015) , our study proposes that alongside the known role of MMP9 in promoting glial invasion (Joseph et al., 2015) , an upregulated MMP9 downstream of inactivated EGFR may have prognostic importance in the process of astrocyte damage.
Our study showed that via an attenuated HB-EGF signaling, neurons could affect the astrocytes of developing brain. Glianeuron interaction has a significant contribution in deciding astrocyte morphology (Rodnight and Gottfried, 2013) . Using arsenic-treated cells and rats, the current study adds that HB-EGF signaling in neurons is also capable of manipulating the astrocytic HB-EGF/EGFR pathway within the developing brain. We found that decreased neuronal HB-EGF inactivated the EGFR and dysregulated HB-EGF/EGFR signaling of adjoining astrocytes, offering an ideal example of autocrine-paracrine EGFR/ HB-EGF signaling involving 2 different cell types within the developing brain. Until now, the nonneuronal cells were considered mainly responsible for the neurotrophic functions of EGFR ligands, particularly HB-EGF, and that too via the neuronal MAPKs (Kornblum et al., 1999,) . On the contrary, our study emphasizes upon the combinatorial response of neuron and astrocytic HB-EGF on astrocytic EGFR-dependent MMP9 signaling and an ultimate modulation in the properties of astrocytes. Thus, our results suggest that arsenic may induce neuron-glia interactions, underscoring the necessity of exploring participating signaling pathways for thorough understanding of the functions and pathophysiology of the developing brain.
It had been indicated that arsenic stimulates an altered cell cycle, inducing astrocyte apoptosis . Here, we identified an attenuated HB-EGF/EGFR-dependent MMP9 to be liable for the arsenic-mediated apoptosis, suggesting that a normal autocrine/paracrine HB-EGF/EGFR signaling and reduced MMP9 may annul apoptosis in the astrocytes. An enhanced EGF and TGF-a/EGFR signaling is known to promote astrocyte proliferation (Rousselet et al., 2012) , and likewise, increased EGFR activation prevented astrocyte apoptosis within the spinal cord (Li et al., 2016) . Not only astrocytes, an attenuated autocrine TGF-a/ EGFR pathway has also been reported in 2, 3, 7, 8-Tetrachlorodibenzo-p-dioxin-induced apoptosis in the epithelial cells (Davis et al., 2001) . Thus, our study reinforces that EGFR signaling, and particularly modulation of its autocrine/paracrine functioning through HB-EGF ligand may play an important role in cellular apoptosis. Our study also supports that toxicants may target HB-EGF/EGFR pathway in mediating pathological effects. It has been proved that Notch signaling plays a critical role in HB-EGF-induced astrocyte responses (Puschmann et al., 2014) . However, our study showing an unchanged Notch expression in astrocytes upon arsenic exposure (Supplementary Figure 18) raises a question as to whether exogenous HB-EGF may have induced the protective response via Notch signaling, that which remains seeing.
Our study depicts that arsenic-mediated decreased HB-EGF/ EGFR signaling ultimately results in BBB disruption. This contradicts earlier observations in hypoxic condition, where BBB damage resulted from increased HB-EGF/EGFR signaling (Ashok et al., 2016) . Increased MMP9 may have been the common reason causing BBB damage for the current as well as previous study that had shown an augmented HB-EGF/EGFR-dependent increased MMP9 activity (Ashok et al., 2016) . Thus, for the present study, it may be assumed that arsenic-induced MMP9 causes degradation of extracellular matrix (ECM), tight junction, and basal laminar proteins that regulate BBB integrity (Kamat et al., 2014; Lapchak et al., 2000) . Besides MMP9, altered GFAP levels and astrocyte morphology could also be important contributors to the BBB damage, based on their important roles in preserving the astrocyte intermediate filaments that control formation of astrocyte end feet and tight junctions of the BBB (Pekny et al., 1998) . Nonetheless, discerning whether arsenicinduced MMP9 truly influences ECM and tight junction proteins is beyond the scope of current investigation and may be considered as a separate study through extensive approaches, such as visualizable dextrans and radiolabeled molecules for qualitative and quantitative appraisal of barrier integrity.
CONCLUSION
Overall, this study indicates that arsenic-mediated developmental brain damage involves an attenuated autocrine/paracrine HB-EGF/EGFR signaling and a downstream astrocytic MMP9, which may cause GFAP damage and BBB disruption. Thus, an HB-EGF/EGFR loop seems important in sustaining physiological functions of the brain, and the targeted activation of this pathway appears to have distinct neuroameliorative role, particularly against arsenic-induced neurodegeneration in children.
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